NASDAQ:EDIT

Editas Medicine Stock Forecast, Price & News

$36.16
+1.16 (+3.31 %)
(As of 06/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$34.02
$36.72
50-Day Range
$31.29
$41.66
52-Week Range
$27.01
$99.95
Volume1.02 million shs
Average Volume1.99 million shs
Market Capitalization$2.45 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.94
30 days | 90 days | 365 days | Advanced Chart
Receive EDIT News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.


Editas Medicine logo

About Editas Medicine

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.35 out of 5 stars

Medical Sector

804th out of 2,100 stocks

Biological Products, Except Diagnostic Industry

117th out of 198 stocks

Analyst Opinion: 3.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Editas Medicine (NASDAQ:EDIT) Frequently Asked Questions

Is Editas Medicine a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 4 sell ratings, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Editas Medicine stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View analyst ratings for Editas Medicine
or view top-rated stocks.

What stocks does MarketBeat like better than Editas Medicine?

Wall Street analysts have given Editas Medicine a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Editas Medicine wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Editas Medicine's next earnings date?

Editas Medicine is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Editas Medicine
.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) issued its quarterly earnings results on Wednesday, May, 5th. The company reported ($0.86) EPS for the quarter, missing the Zacks' consensus estimate of ($0.76) by $0.10. The firm had revenue of $6.50 million for the quarter, compared to the consensus estimate of $5.78 million. Editas Medicine had a negative net margin of 147.51% and a negative trailing twelve-month return on equity of 28.42%. The firm's revenue was up 13.6% compared to the same quarter last year. During the same period last year, the company earned ($0.69) earnings per share.
View Editas Medicine's earnings history
.

How has Editas Medicine's stock price been impacted by Coronavirus?

Editas Medicine's stock was trading at $20.27 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EDIT shares have increased by 78.4% and is now trading at $36.16.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for EDIT?

12 brokerages have issued 12 month target prices for Editas Medicine's shares. Their forecasts range from $14.00 to $86.00. On average, they anticipate Editas Medicine's stock price to reach $46.50 in the next twelve months. This suggests a possible upside of 28.6% from the stock's current price.
View analysts' price targets for Editas Medicine
or view top-rated stocks among Wall Street analysts.

Who are Editas Medicine's key executives?

Editas Medicine's management team includes the following people:
  • Mr. James C. Mullen, Chairman, Pres & CEO (Age 62, Pay $100.5k)
  • Ms. Michelle Robertson, CFO, Principal Accounting Officer, Treasurer & Assistant Sec. (Age 54, Pay $647.26k)
  • Dr. Lisa A. Michaels M.D., Exec. VP & Chief Medical Officer (Age 56, Pay $213.47k)
  • Dr. Feng Zhang, Co-Founder & Scientific Advisory Board Member
  • Dr. George M. Church, Co-Founder & Scientific Advisory Board Member (Age 67)
  • Dr. J. Keith Joung, Co-Founder & Scientific Advisory Board Member
  • Dr. David R. Liu, Co-Founder & Scientific Advisory Board Member
  • Mr. Harry R. Gill III, Sr. VP of Operations (Age 60)
  • Dr. Mark S. Shearman, Exec. VP & Chief Scientific Officer (Age 61)
  • Ms. Charlene Stern, Sr. VP & Chief Legal Officer

Who are some of Editas Medicine's key competitors?

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Square (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

(EDIT) raised $100 million in an initial public offering on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (12.90%), BlackRock Inc. (8.49%), Nikko Asset Management Americas Inc. (6.30%), Sumitomo Mitsui Trust Holdings Inc. (6.25%), Geode Capital Management LLC (1.70%) and Morgan Stanley (1.42%). Company insiders that own Editas Medicine stock include Charles Albright, Cynthia Collins and Michelle Robertson.
View institutional ownership trends for Editas Medicine
.

Which institutional investors are selling Editas Medicine stock?

EDIT stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Federated Hermes Inc., Chevy Chase Trust Holdings Inc., Sumitomo Mitsui Trust Holdings Inc., State of Michigan Retirement System, CloudAlpha Capital Management Limited Hong Kong, Voloridge Investment Management LLC, and Nikko Asset Management Americas Inc.. Company insiders that have sold Editas Medicine company stock in the last year include Charles Albright, Cynthia Collins, and Michelle Robertson.
View insider buying and selling activity for Editas Medicine
or view top insider-selling stocks.

Which institutional investors are buying Editas Medicine stock?

EDIT stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Compagnie Lombard Odier SCmA, Geode Capital Management LLC, Discovery Value Fund, Dimensional Fund Advisors LP, DDD Partners LLC, and Morgan Stanley.
View insider buying and selling activity for Editas Medicine
or or view top insider-buying stocks.

How do I buy shares of Editas Medicine?

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $36.16.

How much money does Editas Medicine make?

Editas Medicine has a market capitalization of $2.45 billion and generates $90.73 million in revenue each year. The company earns $-115,980,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis.

How many employees does Editas Medicine have?

Editas Medicine employs 235 workers across the globe.

What is Editas Medicine's official website?

The official website for Editas Medicine is www.editasmedicine.com.

Where are Editas Medicine's headquarters?

Editas Medicine is headquartered at 11 Hurley Street, Cambridge MA, 02141.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]


This page was last updated on 6/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.